Edition:
United States

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

6.49USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$6.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,908
52-wk High
$9.36
52-wk Low
$4.94

Latest Key Developments (Source: Significant Developments)

Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders
Friday, 8 Dec 2017 05:53pm EST 

Dec 8 (Reuters) - Leap Therapeutics Inc ::LEAP THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.73 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14
Wednesday, 22 Nov 2017 04:29pm EST 

Nov 22 (Reuters) - Eli Lilly And Co :Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing.  Full Article

Leap Therapeutics announces $18 million private placement offering
Wednesday, 15 Nov 2017 07:00am EST 

Nov 15 (Reuters) - Leap Therapeutics Inc ::Announces $18 million private placement offering.Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock​.Signed voting agreement with HealthCare Ventures to vote shares in favor of approval proposed at stockholders​ special meeting.To sell shares in private placement with select institutional investors, strategic partners, including HealthCare Ventures, Eli Lilly.  Full Article

Leap Therapeutics qtrly loss per share $0.73
Monday, 13 Nov 2017 07:00am EST 

Nov 13 (Reuters) - Leap Therapeutics Inc -:Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial.Leap Therapeutics Inc - ‍cash, cash equivalents and marketable securities totaled $14.2 million at September 30, 2017​.Leap Therapeutics Inc - ‍net loss was $6.8 million for Q3 of 2017, compared to $7.3 million for same period in 2016​.Leap therapeutics inc - qtrly loss per share $0.73.  Full Article

Leap Therapeutics announces collaboration with EORTC
Friday, 8 Sep 2017 07:00am EDT 

Sept 8 (Reuters) - Leap Therapeutics Inc :Leap Therapeutics announces collaboration with EORTC to evaluate DKN-01 in combination with PD-l1 cancer immunotherapy and chemotherapy in esophagogastric and biliary tract cancers.Leap Therapeutics Inc - ‍Roche will supply atezolizumab to EORTC for this study collaboration​.Leap Therapeutics Inc - ‍study is expected to begin enrolling patients in 2018​.Leap Therapeutics - ‍study aims to understand synergy between DKN-01, a WNT-targeted therapy, and immune checkpoint inhibitor with and without chemotherapy​.  Full Article

Leap Therapeutics says Q2 loss per share $0.74
Friday, 11 Aug 2017 07:15am EDT 

Aug 11 (Reuters) - Leap Therapeutics Inc :Q2 loss per share $0.74 - SEC filing.  Full Article

Leap Therapeutics Q2 net loss $6.9 mln vs $7.5 mln, a year earlier
Friday, 11 Aug 2017 07:00am EDT 

Aug 11 (Reuters) - Leap Therapeutics Inc :Leap therapeutics reports second quarter 2017 financial results.Leap therapeutics inc - qtrly ‍net loss per share $0,74​.  Full Article

Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study
Wednesday, 21 Jun 2017 05:41pm EDT 

June 21 (Reuters) - Leap Therapeutics Inc -:Leap Therapeutics - under agreement with unit of Merck, Co to sponsor and fund phase i/ii clinical trials of combination of dkn-01 and keytruda(reg).Leap Therapeutics Inc says under agreement, merck will be responsible for manufacturing and supplying Keytruda(reg) for clinical trials - sec filing.Leap Therapeutics Inc - agreement provides that both Leap and Merck will jointly own clinical data generated from this clinical trial.  Full Article

Leap Therapeutics announces collaboration with Merck
Wednesday, 21 Jun 2017 09:07am EDT 

June 21 (Reuters) - Leap Therapeutics Inc :Leap therapeutics announces collaboration with merck to evaluate keytruda® (pembrolizumab) in combination with dkn-01 in esophagogastric cancer.Leap therapeutics inc - additional details of collaboration were not disclosed..Leap therapeutics inc - collaboration agreement is between leap and merck, through a subsidiary.Leap therapeutics inc - study is expected to begin enrolling patients in second-half of 2017.  Full Article

Leap Therapeutics reports qtrly net loss per share $1.39
Friday, 12 May 2017 07:00am EDT 

May 12 (Reuters) - Leap Therapeutics Inc : :Leap Therapeutics reports first quarter 2017 financial results.Leap Therapeutics Inc - net loss was $9.4 million for Q1 of 2017, compared to $5.1 million for same period in 2016.Leap Therapeutics Inc - cash, cash equivalents and marketable securities totaled $23.8 million at March 31, 2017.Leap Therapeutics Inc qtrly net loss per share $1.39.Leap Therapeutics Inc - research and development expenses were $6.4 million for Q1 2017, compared to $4.1 million for same period in 2016.  Full Article

BRIEF-Leap Therapeutics Announces First Patient Dosed With TRX518 Combination Therapy

* LEAP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH TRX518 COMBINATION THERAPY IN ADVANCED SOLID TUMORS TRIAL Source text for Eikon: Further company coverage: